Qurient Enrolls First Patient in Q702 U.S. Phase 1 Study

On January 26, 2021 Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, reported that the first patient was dosed in the Q702 phase 1 study being conducted in the U.S. Q702 is an orally available immuno-oncology small molecule targeting the Axl, Mer, and CSF1 receptor tyrosine kinases (Press release, Qurient Therapeutics, JAN 26, 2021, View Source [SID1234574309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Qurient licensed Q702 from the Max Planck Innovation GmbH in Germany. The initial Q702 basic science research and non-clinical program was conducted by the Max Planck Institute of Biochemistry and Lead Discovery Center in Germany.

Q702 is a first-in-class Axl/Mer/CSF1R triple inhibitor demonstrating significant in vivo activity as a monotherapy as well as in combination with an anti-PD-1 antibody. Q702 not only modulates innate immune components such as myeloid derived suppressor cells (MDSC) and tumor associated macrophages (TAM) in the tumor micro-environment (TME) but also increases MHC I expression in tumor cells.

The Q702 phase 1 study is currently being conducted at three experienced investigative sites in the U.S., and approximately 80 patients with relapsed/refractory advanced solid tumors are expected to be enrolled. The primary objectives of this phase 1 study are to determine (i) the maximum tolerated dose, (ii) the safety profile of Q702, and (iii) the recommended phase 2 dose of Q702.

"Among the three anticancer investigative agents licensed from the Max Planck Innovation, Q702 is the first clinical-stage oncology asset in our oncology pipeline," said Kiyean Nam, Ph.D., CEO of Qurient. "Qurient is an oncology-focused specialty biotechnology company with three oncology assets in the pipeline at various stages of development, and we will continue to expand our oncology pipeline through collaboration with Max Planck Institute and Lead Discovery Center along with other business development opportunities."